While recent successes with of cellular immunotherapies like CAR-T have demonstrated the great promise of adoptive cell therapies for fighting cancer, many challenges remain in reducing T-cell exhaustion, overcoming the immunosuppressive effects of the tumor microenvironment, and successfully applying adoptive cell immunotherapies to wider array of cancers, including solid tumors. Newer technologies engage alternative cell types, like NK cells, or use feats of cellular engineering to improve potency or safety of these promising therapies.
This intellectual property portfolio from Stanford includes technologies to increase the applicability and effectiveness of adoptive T-cell and NK cell therapies, reduce T-cell exhaustion, improve safety, and novel targets.